A Phase 2 interventional study of cabozantinib and abiraterone in Prostate Cancer, Castration Resistant Prostate Cancer and Prostatic Neoplasms, sponsored by Exelixis. Terminated at 20 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Exelixis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 12 in phase 2, and was the 13th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Men only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Exelixis · Sites in United States
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 33 across the 23 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing cabozantinib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05168618University of UtahCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | 2026-11 |
| NCT05613894University of UtahDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
The goal of this clinical trial was to learn if the combination of the drugs cabozantinib and abiraterone works for men that were chemotherapy-naive, bone metastasis CRPC patients. It was designed to learn about the safety of cabozantinib. The main questions are:
Participants were assigned to one of the four treatment groups:
Arm 1. cabozantinib at a dose of 40 mg every day (QD) plus abiraterone with prednisone; Arm 2. cabozantinib at a dose of 20 mg QD plus abiraterone with prednisone; Arm 3. cabozantinib at a dose of 20 mg every other day (QOD) plus abiraterone with prednisone; Arm 4. abiraterone with prednisone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabozantinib 40 mg, by mouth daily (po QD), + abiraterone with prednisone
Drug: cabozantinib · Drug: abiraterone · Drug: prednisone
Cabozantinib 20 mg, by mouth daily (po QD), + abiraterone with prednisone
Drug: cabozantinib · Drug: abiraterone · Drug: prednisone
Cabozantinib 20 mg every other day with abiraterone and prednisone
Drug: cabozantinib · Drug: abiraterone · Drug: prednisone
Abiraterone with prednisone
Drug: abiraterone · Drug: prednisone
Also known as: XL184
Also known as: Zytiga(R), abiraterone acetate
Radiographic Progression Free Survival (PFS)
PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause, as assessed by Independent Radiology Committee (IRC). The sponsor terminated the study early due to business reasons. As such, no data were collected for efficacy analyses.
Time frame: Up to 18 Months
This study enrolled subjects from 11 February 2014 (first patient enrolled) through 02 September 2014 (Sponsor decision to end study). The study was terminated prior to completing enrollment due to Sponsor decision (not based on any safety results).
| Milestone | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only |
|---|---|---|---|---|
| Started | 14 | 13 | 13 | 14 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 14 | 13 | 13 | 14 |
| Withdrew: Sponsor decision to terminate study | 14 | 12 | 12 | 10 |
| Withdrew: Progressive disease | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: No treatment given | 0 | 0 | 0 | 1 |
PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause, as assessed by Independent Radiology Committee (IRC). The sponsor terminated the study early due to business reasons. As such, no data were collected for efficacy analyses.
No measurements were reported for this outcome.
Collected over Up to 7 months. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | 0/14 (0%) | 2/14 (14.3%) | 13/14 (92.9%) |
| Arm 2 | 1/14 (7.1%) | 4/14 (28.6%) | 10/14 (71.4%) |
| Arm 3 | 0/12 (0%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Arm 4 | 1/13 (7.7%) | 1/13 (7.7%) | 11/13 (84.6%) |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/14 | 1/14 | 1/12 | 0/13 |
| HypokalemiaMetabolism and nutrition disorders | 0/14 | 0/14 | 1/12 | 0/13 |
| Atrial fibrillationCardiac disorders | 0/14 | 0/14 | 0/12 | 1/13 |
| PneumoniaInfections and infestations | 0/14 | 0/14 | 0/12 | 1/13 |
| Septic shockInfections and infestations | 0/14 | 0/14 | 0/12 | 1/13 |
| AnemiaBlood and lymphatic system disorders | 1/14 | 0/14 | 0/12 | 0/13 |
| Renal failure acuteRenal and urinary disorders | 1/14 | 0/14 | 0/12 | 0/13 |
| Uncoded: left sided obstructive uropathyRenal and urinary disorders | 1/14 | 0/14 | 0/12 | 0/13 |
| Myocardial infarctionCardiac disorders | 1/14 | 0/14 | 0/12 | 0/13 |
| BronchitisInfections and infestations | 0/14 | 1/14 | 0/12 | 0/13 |
| Event | Arm 1 | Arm 2 | Arm 3 | Arm 4 |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/14 | 1/14 | 1/12 | 4/13 |
| FatigueGeneral disorders | 4/14 | 3/14 | 2/12 | 3/13 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/14 | 4/14 | 2/12 | 3/13 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 4/14 | 1/14 | 0/12 | 1/13 |
| HypertensionVascular disorders | 3/14 | 3/14 | 3/12 | 2/13 |
| VomitingGastrointestinal disorders | 0/14 | 2/14 | 1/12 | 3/13 |
| Blood alkaline phosphatase increasedInvestigations | 1/14 | 0/14 | 1/12 | 3/13 |
| DizzinessNervous system disorders | 1/14 | 0/14 | 1/12 | 3/13 |
| InsomniaPsychiatric disorders | 2/14 | 1/14 | 0/12 | 3/13 |
| Aspartate aminotransferase increasedInvestigations | 3/14 | 0/14 | 0/12 | 0/13 |
| Age, Categorical(Participants) | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 3 | 3 | 10 |
| >=65 years | 12 | 11 | 10 | 11 | 44 |
| Age, Continuous(years) | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only | Total |
|---|---|---|---|---|---|
| Median | 76 (56 to 87) | 74 (61 to 83) | 73 (63 to 76) | 70 (55 to 84) | 73 (55 to 87) |
| Sex: Female, Male(Participants) | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 14 | 13 | 13 | 14 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 13 | 12 | 13 | 14 | 52 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 3 | 2 | 8 |
| White | 13 | 10 | 10 | 12 | 45 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm 1 - Cabozantinib 40 mg, po QD + Abiraterone | Arm 2 - Cabozantinib 20 mg, po QD + Abiraterone | Arm 3 - Cabozantinib 20 mg, po QOD + Abiraterone | Arm 4 - Abiraterone Only | Total |
|---|---|---|---|---|---|
| United States | 14 | 13 | 13 | 14 | 54 |
The record gives a start of Feb 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2026, 11 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib